Predict your next investment

Holding Company
BUSINESS PRODUCTS & SERVICES | Consulting & Outsourcing / Management & Strategy Consulting
red-stars.com

See what CB Insights has to offer

Investments

5

About red-stars.com

The red-stars.com data is an operative holding company whose companies specialize exclusively in B2B digitization processes. The focus is on EDI / SRM, rapid prototyping and processes, IoT connectivity, video analytics, big data, AI, cloud compliance and technology-driven models of the B2B sharing economy and life science spin-offs.

red-stars.com Headquarter Location

Graben 14/B26

Vienna, 1010,

Austria

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest red-stars.com News

HeartBeat bio : to Reinvent Cardiac Drug Discovery

May 4, 2021

05/04/2021 | 04:01am EDT Message : HeartBeat.bio AG to Reinvent Cardiac Drug Discovery 04.05.2021 / 10:00 HeartBeat.bio AG to Reinvent Cardiac Drug Discovery World-wide first self-organizing human cardiac organoids (Cardioids) for high-throughput drug screening Technology licensed from renowned Vienna Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) Company launched based on seed financing by red-stars.com data AG Vienna, Austria - 04 May 2021 - HeartBeat.bio AG, a spin-off company of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), today announced that it has established its operations with seed financing of EUR 1.5 million from red-stars.com data AG. The Company is developing a high-throughput 3D screening platform for heart diseases using the world-wide first self-organizing human cardiac organoids (Cardioids). The Cardioid technology has been invented by the Mendjan lab at IMBA, one of the global leading hubs in organoid research. HeartBeat.bio has signed an exclusive license and collaboration agreement with IMBA and will closely cooperate with the research group of Sasha Mendjan to further develop the technology. Cardioids are a stem-cell derived, multi-cellular, 3D tissue culture system that recapitulates the human heart physiology and the most clinically relevant left ventricular chamber in an unprecedented way. This human organoid screening platform enables the automated, reproducible, and cost-effective large-scale generation and analysis of cardiac organoids, making it suitable for high-throughput compound screenings. The drug discovery program will focus on heart failure and cardiomyopathies as well as cardiotoxicity studies for new drug candidates. HeartBeat.bio was founded by an experienced team of biotech entrepreneurs and IMBA scientists: Michael Krebs, CEO of HeartBeat.bio and former Managing Director of IMBA, Sasha Mendjan, Principal Investigator of the Human Cardiogenesis Team at IMBA, Oliver Szolar, CEO of a:head bio AG and Pablo Hofbauer, co-inventor of the Cardioid technology and Head of Organoid Research at HeartBeat.bio. Michael Krebs, CEO of HeartBeat.bio said: "We strongly believe that the Cardioid-based screening platform has the potential to radically change the cardiovascular drug discovery paradigm resulting in higher clinical trial success rates and reduced cost and time for compound development." "Our curiosity-driven research has revealed innovative and radically new possibilities for drug development. The founding of HeartBeat.bio demonstrates the benefits of basic research for taxpayers and the economic well-being. We are very proud of being able to contribute to its success", added Jürgen Knoblich, Scientific Director of IMBA. Thomas Streimelweger, CEO of red-stars.com data AG, commented: "HeartBeat.bio is an extremely promising academic spin-off with great potential to revolutionize cardiac drug discovery. The market for major heart disease prescription drugs has an annual volume of over US $ 60 billion and there is a high unmet medical need to discover new drugs for difficult-to-treat diseases such as heart failure and cardiomyopathies." The gross proceeds of the seed financing will be used to establish operations, build up an experienced team over the next 12 months, and develop the Cardioid technology into a platform solution for compound screening. Besides red-stars' seed investment, HeartBeat.bio has already received financial support from AWS - via the AWS Pre-Seed Program which is funded by the Austrian Federal Ministry for Digital and Economic Affairs (BMDW) and the Federal Ministry for Climate Action, Environment, Energy, Mobility, Innovation and Technology (BMK) - and from Vienna's high-tech incubator INiTS via its AplusB Scaleup Program. About HeartBeat.bio HeartBeat.bio AG is dedicated to developing the first high-throughput human organoid screening platform for cardiac drug discovery. The screening platform is built on self-organizing, highly scalable cardiac organoids which recapitulate the human heart physiology and enable modeling of diseases such as heart failure and cardiomyopathies as well as cardiotoxicity. HeartBeat.bio AG was founded in 2021 based on technology from the Institute of Molecular Biotechnology (IMBA) by a seasoned team with in-depth experience in organoid research, drug discovery and business development. The Company is located at the Vienna BioCenter in Austria. For further information, please visit www.heartbeat.bio or follow us on LinkedIn . About IMBA IMBA - Institute of Molecular Biotechnology of the Austrian Academy of Sciences - is one of the leading biomedical research institutes in Europe focusing on cutting-edge stem cell technologies, functional genomics, and RNA biology. IMBA is located at the Vienna BioCenter, a vibrant cluster of universities, research institutes and biotech companies in Austria. IMBA is a subsidiary of the Austrian Academy of Sciences, the leading national sponsor of non-university academic research. The stem cell and organoid research at IMBA is being funded by the Austrian Federal Ministry of Science and the City of Vienna. About red-stars.com data AG red-stars.com data AG is an operative holding company engaged in the global penetration of highly scalable innovative technologies, utilizing and commercializing scientific IP and software. Contact:

red-stars.com Investments

5 Investments

red-stars.com has made 5 investments. Their latest investment was in Txture as part of their Unattributed on June 6, 2021.

CBI Logo

red-stars.com Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/16/2021

Unattributed

Txture

No

1

5/4/2021

Seed

Subscribe to see more

$99M

Subscribe to see more

10

8/7/2019

Seed

Subscribe to see more

Subscribe to see more

10

6/4/2019

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

6/30/2000

Seed

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/16/2021

5/4/2021

8/7/2019

6/4/2019

6/30/2000

Round

Unattributed

Seed

Seed

Corporate Minority

Seed

Company

Txture

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

red-stars.com Team

4 Team Members

red-stars.com has 4 team members, including current Chief Executive Officer, Thomas Huber.

Name

Work History

Title

Status

Thomas Huber

Chief Executive Officer

Current

Thomas Streimelweger

Chief Executive Officer

Current

Georg Schoder CFA

Chief Financial Officer

Current

Jan Postuma

Chief Information Officer

Current

Name

Thomas Huber

Thomas Streimelweger

Georg Schoder CFA

Jan Postuma

Work History

Title

Chief Executive Officer

Chief Executive Officer

Chief Financial Officer

Chief Information Officer

Status

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.